Trade Seattle Genetics

Seagen is an American biotechnology company that focuses on the development and marketing of innovative antibody-based monoclonal antibodies to cancer treatment. The company, based in Boyle, Washington (a suburb of Seattle), is a leader in the anti-drug facility industry or ADCs, a technology designed to harness the targeted ability of monoclonal antibodies to deliver cell killing agents directly to cancer cells. Conjugates are intended to spare non-target cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially promoting antitumor activity. the company's main product Adcetris (Brentuximab vedotin) is commercially available for four indicators in more than 65 countries, including the United States, Canada, Japan and members of the European Union. to expand the clinical opportunities for vedotin printex, Seattle Genetics conducts a broad clinical development program to evaluate its therapeutic potential in previous lines of approved indicators as well as in a range of other lymphocytic and non-lymphatic settings. The company is developing brentuximab vedotin in collaboration with Takeda Pharmaceuticals. Under the terms of the cooperation, Seattle Genetics has full marketing rights for brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to market the product candidate in all other countries.